


# Biosimilar Use in Cancer Treatment

## Are Specialists Ready?


Biosimilars are already in use in other therapeutic areas in Canada, but are only now becoming available in oncology.

MD Analytics explored the attitudes and perceptions of 31 Oncologists and Hematologists regarding biosimilars.

The majority of Oncologists and Hematologists have some knowledge of biosimilars, **but there is room to improve familiarity:**



### Biologics vs. Biosimilars



Biological products (medicines derived from biological processes) are genericized as **biosimilars**: drugs that closely mimic existing name-brand biologics.

**Biosimilars** are not exact copies of the biologic reference product due to the complexity of their production process, but they must demonstrate therapeutic equivalency in order to be considered biosimilars.

3 in 4 specialists acknowledge **biosimilars will aid patient access to optimal cancer treatments.**



However,

**Only 1 in 10 strongly agree** that they are **looking forward to prescribing biosimilars.**



## Why is enthusiasm for biosimilars not stronger?

Specialists have lingering concerns regarding:



**Subpar patient support**  
(84%)



**Replicability**  
(74%)



**Payers mandating treatment changes**  
(74%)



**Disincentive to innovation**  
(65%)



Data based on survey of n=31 Canadian Oncologists and Hematologists. August 2018.

**MD Analytics**  
www.mdanalytics.com

Copyright © 2018 MD Analytics Inc. MD Analytics is a registered trademark of MD Analytics Inc. All rights reserved.